• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 12, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New leukemia treatment outperforms standard chemotherapies

Bioengineer by Bioengineer
June 8, 2017
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at The Australian National University (ANU) are working on a new treatment for an aggressive type of leukemia that outperforms standard chemotherapies.

Lead researcher Dr Nadine Hein from The John Curtin School of Medical Research at ANU said researchers have successfully treated highly aggressive acute myeloid leukemia (AML) in mice using the new treatment.

"Not only have we been able to reduce the number of cancer cells, we have been able to reduce the number of cancer stem cells that tend to develop or be resistant to chemotherapy and are thought to be responsible for disease relapse in patients," Dr Hein said.

Dr Hein said researchers used a compound known as CX-5461 to target the protein-making process within the cancer cells.

"We are working towards a treatment that will improve on the current chemotherapy options and improve the patient's prognosis," Dr Hein said

Around 1,000 people are diagnosed with AML in Australia each year and, depending on the patient's age, there is a high rate of mortality with only about 30 percent surviving long term.

Canberra haematologist and ANU Senior Lecturer Dr James D'Rozario said the standard approach to treating AML hasn't changed in over 30 years.

"Novel agents such as CX-5461 with more sophisticated mechanisms of action are desperately required to improve outcomes in patients with this group of illnesses," Dr D'Rozario said.

Professor Ross Hannan, Head of the ACRF Department of Cancer Biology and Therapeutics at JCSMR, said that based on the promising preclinical results, a Phase 1 clinical trial for the treatment of patients with blood cancer has just been completed in Australia. Results are expected to be published later this year.

"Another Phase 1/ Phase 2 clinical trial is underway in Canada for the treatment of patients with solid tumours," Professor Hannan said.

###

The research has been published in Blood: http://www.bloodjournal.org/content/129/21/2882?sso-checked=true

For media assistance, contact Kate Prestt in the ANU media team on +61 2 6125 7979, or email [email protected].

Media Contact

Kate Prestt
[email protected]
61-261-257-979
@ANUmedia

http://www.anu.edu.au/media

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Violence Against Women in North-East Piedmont Emergency Rooms

November 12, 2025

Shift Work and Chronotype Affect Hong Kong Nurses’ Sleep

November 12, 2025

Next-Generation Nanoparticle-Stem Cell Hybrids Pave the Way for Advanced Bone Regeneration

November 12, 2025

Validating Schema Modes for Eating Disorders and Personality

November 12, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    317 shares
    Share 127 Tweet 79
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    208 shares
    Share 83 Tweet 52
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    140 shares
    Share 56 Tweet 35
  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1305 shares
    Share 521 Tweet 326

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

RPL17 Drives Breast Cancer via MAPK Activation

Violence Against Women in North-East Piedmont Emergency Rooms

Transperineal Prostate Biopsy: Safety Without Antibiotics

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.